Presented by Narinder Bhalla, MD, FACC, FSCAI, and Curtis Triplitt, PharmD, CDE, this webinar will focus on the intersection of cardiovascular disease and diabetes. It will start with the types of CVD encountered in patients with T2D, and their overall frequency, associated features and prognosis. We will define primary and secondary prevention and some of the nuanced differences in the definitions amongst cardiologists and diabetologists/endocrinologists. We will go through the tried and true therapies in managing CVD in patients with T2D, and some of the controversy surrounding the role of aspirin in primary prevention (some of the recent trial will be discussed). The EASD updated statement in managing patients with T2DM will be discussed, and will be used as an example of the changing paradigm of using the presence of CVD as a pivot point in the treatment. We will then end with the future trials, and their designs and the questions they will seek to answer.
Upon completion of this activity, participants will be able to:
- Understand the epidemiology of the various cardiovascular comorbidities that coexist in the patient with T2D
- Be able to discuss primary and secondary prevention and understand the definitions
- Understand the new paradigm in treating patients with diabetes, with the type of CVD being a pivot point in treatment choices